ClinicalTrials.gov
ClinicalTrials.gov Menu

BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study (BACCARAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02605512
Recruitment Status : Recruiting
First Posted : November 16, 2015
Last Update Posted : June 19, 2018
Sponsor:
Collaborators:
Institut de Radioprotection et de Surete Nucleaire
Clinique Pasteur
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
Sophie JACOB, Institut de Radioprotection et de Surete Nucleaire

November 6, 2015
November 16, 2015
June 19, 2018
October 2015
September 2019   (Final data collection date for primary outcome measure)
  • Number of patients with decreased myocardial function assessed by echocardiography [ Time Frame: 2 years after 3DCRT (baseline measures performed before radiotherapy) ]
    Number of patients with a decrease in the mean strain or strain rate measured from the echocardiography of the order of 5% between the measurement before RT and 24 months after RT
  • Number of patients with increased coronary plaques assessed by CT coronary angiography [ Time Frame: 2 years after 3DCRT (baseline measures performed before radiotherapy) ]
    Number of patients with an increase of the average index of coronary plaques measured from the CT coronary angiography in the order of 15% between the measurements before RT and 24 months after RT
Same as current
Complete list of historical versions of study NCT02605512 on ClinicalTrials.gov Archive Site
  • Decrease in the strain or strain rate [ Time Frame: 6 months after 3DCRTand 2 years after 3DCRT (baseline measures performed before radiotherapy) ]
  • Modification in series of circulating biomarkers of cardiac lesions [ Time Frame: 5 weeks after initiation of 3DCRT (corresponding to the end of 3DCRT sessions), 6 months after 3DCRTand 2 years after 3DCRT (baseline measures performed before radiotherapy) ]
    Classical biomarkers of cardiac injury: C-reactive protein, Troponin I, B-type natriuretic peptide (NT-Pro BNP), beta2-Microglobulin, Galectin 3 / Inflammatory cytokines: Interleukin 6, Interleukin 8, Interleukin 18, TNF-α / Endothelial activation and dysfunction: sVCAM,-1 , s-ICAM-1, E-selectin, P-selectin , vWF, PAI-1, Fibrinogen , Thrombomodulin, TGF-β1 / Microparticles: CD14, CD31, CD41, CD3, CD235a / microRNAs : miR-1, miR-133, miR-208, miR-499, miR-126, miR-130, miR-145, miR-181, miR-150, miR-155, miR-223, miR-17, miR-18, miR-22, miR-34, miR-92, miR-140, miR-182, miR-199, miR-423, miR-590
  • Correlation between the absorbed radiation dose by the whole heart and different structures of the heart and measurements of strain and strain rate and indices of coronary plaques [ Time Frame: 2 years ]
Same as current
Not Provided
Not Provided
 
BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study
Early Detection and Prediction of Cardiotoxicity in Radiotherapy-treated Breast Cancer Patients
Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications. Since the 2000s, improvements have appeared in dose distributions to organ at risks such as heart, but now, little is known on the risk of potential cardiac impairment in this population, in particular for chemotherapy naive patients. Based on the state that clinically detectable cardiotoxicity is generally preceded by subclinical cardiac dysfunctions, the aim of the BACCARAT study (BreAst Cancer and Cardiotoxicity induced by RAdioTherapy) is to evaluate whether adjuvant 3DCRT induces cardiac toxicity that could be detected in the first two years after treatment based on a global approach with repeated analysis of subclinical functional and anatomical cardiac lesions in myocardial and coronary levels and circulating biomarkers.

BACCARAT study consists in a monocentric prospective cohort study that will finally include 120 women treated with adjuvant RT for breast cancer in the Clinique Pasteur in Toulouse, and followed for 2 years after RT.

Women aged 50 to 70 years, treated for breast cancer and for whom adjuvant 3DCRT is indicated, without chemotherapy are eligible for the study.

Baseline and follow-up include measures of functional myocardial dysfunction based on 2D-speckle tracking echocardiography, anatomical coronary lesions based on Coronary computed tomography angiography, and a wide panel of circulating biomarkers. Absorbed doses is evaluated for whole heart and for each different parts of heart, in particular coronary arteries.

Analysis on occurrence and evolutions of subclinical cardiac lesions and biomarkers will be performed and completed with dose-response relations with absorbed doses of different heart segments.

Interventional
Not Applicable
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
  • Breast Cancer
  • Cardiac Toxicity
Other: Subclinical cardiac lesions and biomarkers
Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
Breast cancer patients with 3DCRT
Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'
Intervention: Other: Subclinical cardiac lesions and biomarkers

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
Same as current
September 2020
September 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age between 50 and 70 years
  • Women surgically treated for left or right breast cancer and for whom adjuvant treatment is radiotherapy with irradiation of the breast or chest wall irradiation and possibly ganglion chains,
  • Adjuvant radiotherapy with 3DCRT performed in Clinique Pasteur Toulouse
  • WHO performance status ECOG - Eastern Cooperative Oncology Group (index normally used to describe the patient's condition) = 0 or 1
  • Being volunteer to participate in the study and have signed the consent form

Exclusion Criteria:

  • Indication of adjuvant chemotherapy
  • Clinically or radiologically detectable metastasis
  • Personal history of coronary artery disease or myocardial disease
  • Personal history of breast cancer or other cancer requiring radiotherapy to the thorax
  • Patient with controlled infection or severe disease and / or non-hazardous to their participation in the study
  • Contraindications to injection of iodinated contrast (for CCTA): pregnancy, renal failure, allergy.
  • Pregnancy, lactation
  • Abnormal echocardiography before radiotherapy:
  • LVEF <50%
  • Longitudinal strain> - 16%
  • Longitudinal strain rate <1% / s
  • Abnormal wall motion
  • CCTA before radiotherapy showing that therapeutic management is required (coronary-artery calcium (CAC) score>600)
Sexes Eligible for Study: Female
50 Years to 70 Years   (Adult, Older Adult)
No
Contact: Sophie Jacob, PhD +33630704719 sophie.jacob@irsn.fr
France
 
 
NCT02605512
IRSN_2015-A00990-49
No
Not Provided
Not Provided
Sophie JACOB, Institut de Radioprotection et de Surete Nucleaire
Sophie JACOB
  • Institut de Radioprotection et de Surete Nucleaire
  • Clinique Pasteur
  • Institut National de la Santé Et de la Recherche Médicale, France
Principal Investigator: Atul Pathak, MD PhD Clinique Pasteur Toulouse
Institut de Radioprotection et de Surete Nucleaire
June 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP